Protocol Ledger

NCT07687459 · Phase III · RECRUITING

Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Interventional Phase III clinical trial protocol NCT07687459 sponsored by InSilico Medicine Hong Kong Limited in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-09 Enrollment: 320 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07687459
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)320 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07687459
Protocol FieldVerified Registry Value
NCT IdentifierNCT07687459
Consolidated Lead SponsorInSilico Medicine Hong Kong Limited
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment320 participants (ESTIMATED)
Registered Start Date2026-09-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI